CYP51A1 and potassium-aggravated myotonia: Fluconazole depletes the ergosterol pool by blocking removal of the methyl group at C-14 position of a biosynthetic precursor catalyzed by sterol 14-demethylase (CYP51).[8–11] Fluconazole belongs to the ‘conazole’ pedigree of antifungal agents targeting CYP51.[12] This drug class also includes miconazole, ketoconazole, voriconazole and itraconazole that were previously reported to exhibit amoebicidal effect against N. fowleri in vitro.[13–17] Fluconazole and miconazole have also been used in combination with other drugs as part of treatment regimens in human PAM patients.[6, 18, 19]